Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Rani Therapeutics Holdings Inc (RANI)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
11/05/2025: RANI (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
4 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $9.5
1 Year Target Price $9.5
| 2 | Strong Buy |
| 2 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -11.08% | Avg. Invested days 29 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  4.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 11/05/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 291.87M USD | Price to earnings Ratio - | 1Y Target Price 9.5 |
Price to earnings Ratio - | 1Y Target Price 9.5 | ||
Volume (30-day avg) 4 | Beta 0.4 | 52 Weeks Range 0.39 - 3.87 | Updated Date 11/5/2025 |
52 Weeks Range 0.39 - 3.87 | Updated Date 11/5/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.9 |
Earnings Date
Report Date 2025-11-12 | When - | Estimate -0.1667 | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -3796.75% |
Management Effectiveness
Return on Assets (TTM) -93.94% | Return on Equity (TTM) -1187.52% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 35589605 | Price to Sales(TTM) 243.23 |
Enterprise Value 35589605 | Price to Sales(TTM) 243.23 | ||
Enterprise Value to Revenue 29.66 | Enterprise Value to EBITDA -1.42 | Shares Outstanding 97541221 | Shares Floating 17248152 |
Shares Outstanding 97541221 | Shares Floating 17248152 | ||
Percent Insiders 5.9 | Percent Institutions 27.64 |
Upturn AI SWOT
Rani Therapeutics Holdings Inc
Company Overview
History and Background
Rani Therapeutics Holdings, Inc. was founded in 2012. The company is focused on developing and commercializing novel, orally administered biologics. Its lead product candidate is the RaniPill HC, an orally administered capsule intended to deliver biologics, peptides, and proteins.
Core Business Areas
- Oral Biologics Delivery: Rani Therapeutics focuses on developing a platform technology, the RaniPill, for the oral delivery of biologics that are typically administered via injection.
Leadership and Structure
Mir Imran is the Chairman and CEO. The company has a board of directors and a management team focused on research, development, and commercialization.
Top Products and Market Share
Key Offerings
- RaniPill HC: The RaniPill HC is Rani Therapeutics' lead product candidate, designed for oral delivery of human parathyroid hormone analog (PTH) for the treatment of osteoporosis. It is still in clinical trials. Competitors for osteoporosis treatment include Amgen (Prolia), Eli Lilly (Forteo), and Radius Health (Tymlos), which are injectables. No direct oral biologic competitor exists yet.
Market Dynamics
Industry Overview
The pharmaceutical industry is seeing increased interest in oral biologics delivery as a means to improve patient compliance and convenience. The market is competitive, with established players and emerging biotech companies exploring new delivery methods.
Positioning
Rani Therapeutics is positioned as a leader in oral biologics delivery using its RaniPill platform. Its competitive advantage lies in its innovative approach to delivering biologics orally.
Total Addressable Market (TAM)
The TAM for injectable biologics (which Rani aims to replace orally) is estimated to be billions of dollars annually. Rani is positioned to capture a portion of this TAM with successful development and commercialization of its RaniPill platform.
Upturn SWOT Analysis
Strengths
- Novel oral biologics delivery platform
- Potential to improve patient compliance
- Experienced leadership team
- Strong intellectual property portfolio
Weaknesses
- Clinical trial risks
- Dependence on successful development of RaniPill platform
- Limited commercialized products
- High cash burn rate
Opportunities
- Partnerships with pharmaceutical companies
- Expansion to new therapeutic areas
- Growing demand for oral biologics
- Positive clinical trial results
Threats
- Competition from other drug delivery technologies
- Regulatory hurdles
- Failure to achieve clinical trial endpoints
- Patent challenges
Competitors and Market Share
Key Competitors
- AMGN
- LLY
- RDUS
Competitive Landscape
Rani Therapeutics' advantage lies in its oral biologics delivery platform. However, it faces competition from established pharmaceutical companies with approved injectable biologics.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is measured by the advancement of the RaniPill platform through clinical trials.
Future Projections: Future growth is contingent on successful clinical trials, regulatory approvals, and commercialization of the RaniPill platform. Analyst estimates vary widely.
Recent Initiatives: Recent initiatives include ongoing clinical trials for RaniPill HC and exploration of new therapeutic areas for the RaniPill platform.
Summary
Rani Therapeutics is a promising company developing a novel oral biologics delivery platform. Its success hinges on positive clinical trial results and regulatory approvals. High R&D costs and competition pose significant challenges, but the potential market for oral biologics is large. They need to watch for financial strains if they have clinical trial failure.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Analyst reports
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Market share data is approximate and may vary. Consult with a qualified financial advisor before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Rani Therapeutics Holdings Inc
Exchange NASDAQ | Headquaters San Jose, CA, United States | ||
IPO Launch date 2021-07-30 | CEO & Director Mr. Talat Imran | ||
Sector Healthcare | Industry Biotechnology | Full time employees 105 | Website https://www.ranitherapeutics.com |
Full time employees 105 | Website https://www.ranitherapeutics.com | ||
Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company, focusing on technologies to enable the administration of biologics and drugs orally for patients, physicians, and healthcare systems with a alternative to painful injections in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies. Its product pipeline includes RT-102, a parathyroid hormone that is in Phase I clinical trial for the treatment of osteoporosis; RT-105, an anti-TNF-alpha antibody that is in preclinical studies to treat psoriatic arthritis; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; RT-116 which is in discovery stage for the treatment of obesity; and RT-111, an ustekinumab biosimilar for the treatment of various inflammatory conditions. The has a collaboration agreement with ProGen Co., Ltd. for the o-development and commercialization of RT-114 to treat obesity. Rani Therapeutics Holdings, Inc. was founded in 2012 and is headquartered in San Jose, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.